bpc-157 safety fda status Repost @peptides with @use.repost ・・・ BREAKING NEWS! Today's 8–6 advisory vote for is one of the biggest peptide regulatory developments we've seen in years. While nothing changes immediately, the recommendation represents FDA's Overreach on Compounded Peptides

Common Mild Side Effects These typically appear during the first few weeks of use: Increased hunger Especially with Ipamorelin due to ghrelin receptor stimulation Mild water retention Often resolves after the body adjusts Tingling or numbness Usually in fingers or hands (transient) Lightheadedness More common with higher doses or low-carb diets Most of these effects are dose-dependent and subside within a week or two

The 2026 edition became effective October 1, 2025, under the standard annual ICD-10-CM update cycle maintained by NCHS

The FDA has cleared multiple laser devices for fat reduction and body contouring after rigorous evaluation of clinical data

KPV has interesting cell and animal data, especially around intestinal inflammation and inflammatory signaling